At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 29 enrolled
Drug / intervention
Topotecan +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I, Dosage-finding and Pharmacokinetic Study of Intravenous Topotecan and Oral Erlotinib in Adults With Refractory Solid Tumors
Accelerated Community Oncology Research Network·interventional·Posted Feb 11, 2008·Updated Aug 22, 2011
In Brief
A Phase 1 clinical trial evaluating Topotecan and Erlotinib for Metastatic Solid Tumor. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine the best dose of the combination of two approved drugs, intravenous topotecan and oral erlotinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMetastatic Solid Tumor
CountriesUnited States
CollaboratorsGlaxoSmithKline, Genentech, Inc.
Timeline
Phase 1CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJun 2006
First PostedFeb 2008
Primary CompletionAug 2009
TodayJul 2026
First PostedFeb 11, 2008
Enrollment StartJun 1, 2006
Primary CompletionAug 1, 2009
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 18.4 years ago
Interventions
Topotecandrug
All subjects receive treatment with intravenous topotecan and oral erlotinib.
Erlotinibdrug
All subjects receive treatment with intravenous topotecan and oral erlotinib.